- Investor's Business Daily•2 days ago
Kite Pharma showed better-than-expected results for a Phase II trial for its treatment for Non-Hodgkin lymphoma.
- Benzinga•2 days ago
Kite Pharma Inc (NASDAQ: KITE ) saw its shares rally sharply in the after hours Tuesday. The reason: Interim results from the Phase II clinical trial of its lead cancer drug candidate, named KTE-C19, meant ...
Novartis AG (NVS)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||80.83 x 5800|
|Ask||80.93 x 3000|
|Day's Range||80.64 - 81.39|
|52wk Range||69.90 - 95.11|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||29.00|
|Avg Vol (3m)||1,309,048|
|Dividend & Yield||2.72 (3.36%)|